APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biliary Tumor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biliary Tumor Market Analysis and Forecast 2026-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchBiliary Tumor Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Biliary Tumor Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Biliary Tumor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biliary Tumor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Biliary Tumor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Biliary Tumor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biliary Tumor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biliary Tumor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biliary Tumor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biliary Tumor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biliary Tumor include Novartis, GlaxoSmithKline, Southwest Oncology Group, NuCana and NeoGenomics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biliary Tumor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biliary Tumor, also provides the revenue of main regions and countries. Of the upcoming market potential for Biliary Tumor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biliary Tumor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biliary Tumor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biliary Tumor revenue, projected growth trends, production technology, application and end-user industry.

Biliary Tumor Segment by Company

Novartis

GlaxoSmithKline

Southwest Oncology Group

NuCana

NeoGenomics

Biliary Tumor Segment by Type

Mecine

Surgery

Other

Biliary Tumor Segment by Application

Hospitals

Clinics

Other

Biliary Tumor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biliary Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biliary Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biliary Tumor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biliary Tumor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biliary Tumor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biliary Tumor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biliary Tumor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Mecine Major Player Table 3. Surgery Major Player Table 4. Other Major Player Table 5. Global Biliary Tumor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Other Major Player Table 9. Biliary Tumor Industry Trends Table 10. Biliary Tumor Industry Drivers Table 11. Biliary Tumor Industry Opportunities and Challenges Table 12. Biliary Tumor Industry Restraints Table 13. Global Biliary Tumor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Biliary Tumor Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Biliary Tumor Market Share by Region (2021-2026) Table 16. Global Biliary Tumor Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Biliary Tumor Market Share by Region (2027-2032) Table 18. Global Biliary Tumor Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Biliary Tumor Revenue Market Share by Players (2021-2026) Table 20. Global Biliary Tumor Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Biliary Tumor Key Players Headquarters & Area Served Table 22. Global Biliary Tumor Players, Product Type & Application Table 23. Global Biliary Tumor Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Biliary Tumor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Biliary Tumor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Biliary Tumor Revenue Market Share by Type (2021-2026) Table 30. Global Biliary Tumor Revenue Market Share by Type (2027-2032) Table 31. Global Biliary Tumor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Biliary Tumor Revenue Market Share by Application (2021-2026) Table 35. Global Biliary Tumor Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis Biliary Tumor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis Biliary Tumor Product Portfolio Table 40. Novartis Recent Development Table 41. GlaxoSmithKline Company Information Table 42. GlaxoSmithKline Business Overview Table 43. GlaxoSmithKline Biliary Tumor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. GlaxoSmithKline Biliary Tumor Product Portfolio Table 45. GlaxoSmithKline Recent Development Table 46. Southwest Oncology Group Company Information Table 47. Southwest Oncology Group Business Overview Table 48. Southwest Oncology Group Biliary Tumor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Southwest Oncology Group Biliary Tumor Product Portfolio Table 50. Southwest Oncology Group Recent Development Table 51. NuCana Company Information Table 52. NuCana Business Overview Table 53. NuCana Biliary Tumor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. NuCana Biliary Tumor Product Portfolio Table 55. NuCana Recent Development Table 56. NeoGenomics Company Information Table 57. NeoGenomics Business Overview Table 58. NeoGenomics Biliary Tumor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NeoGenomics Biliary Tumor Product Portfolio Table 60. NeoGenomics Recent Development Table 61. North America Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Biliary Tumor Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Biliary Tumor Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Biliary Tumor Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Biliary Tumor Revenue by Country (US$ Million) & (2027-2032) Table 75. China Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 76. China Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 77. China Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 78. China Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Biliary Tumor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Biliary Tumor Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Biliary Tumor Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Biliary Tumor Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Biliary Tumor Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Biliary Tumor Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Biliary Tumor Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Biliary Tumor Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Biliary Tumor Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Biliary Tumor Image Figure 2. Global Biliary Tumor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biliary Tumor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Mecine Image Figure 5. Surgery Image Figure 6. Other Image Figure 7. Global Biliary Tumor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Biliary Tumor Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Other Image Figure 12. Global Biliary Tumor Market Size (US$ Million) & (2021-2032) Figure 13. Global Biliary Tumor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Biliary Tumor Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Biliary Tumor Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Biliary Tumor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biliary Tumor Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Biliary Tumor Revenue Market Share by Type (2021-2032) Figure 20. Global Biliary Tumor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Biliary Tumor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Biliary Tumor Revenue Market Share by Application (2021-2032) Figure 23. North America Biliary Tumor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Biliary Tumor Revenue Share by Type (2021-2032) Figure 25. North America Biliary Tumor Revenue Share by Application (2021-2032) Figure 26. North America Biliary Tumor Revenue Share by Country (2021-2032) Figure 27. United States Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Biliary Tumor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Biliary Tumor Revenue Share by Type (2021-2032) Figure 32. Europe Biliary Tumor Revenue Share by Application (2021-2032) Figure 33. Europe Biliary Tumor Revenue Share by Country (2021-2032) Figure 34. Germany Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Biliary Tumor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Biliary Tumor Revenue Share by Type (2021-2032) Figure 44. China Biliary Tumor Revenue Share by Application (2021-2032) Figure 45. Asia Biliary Tumor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Biliary Tumor Revenue Share by Type (2021-2032) Figure 47. Asia Biliary Tumor Revenue Share by Application (2021-2032) Figure 48. Asia Biliary Tumor Revenue Share by Region (2021-2032) Figure 49. Japan Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Biliary Tumor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Biliary Tumor Revenue Share by Type (2021-2032) Figure 57. SAMEA Biliary Tumor Revenue Share by Application (2021-2032) Figure 58. SAMEA Biliary Tumor Revenue Share by Country (2021-2032) Figure 59. Brazil Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Biliary Tumor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Mecine
  • Surgery
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Novartis
  • GlaxoSmithKline
  • Southwest Oncology Group
  • NuCana
  • NeoGenomics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biliary Tumor Market by Type
  3. 1.2.1 Global Biliary Tumor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Mecine
  5. 1.2.3 Surgery
  6. 1.2.4 Other
  7. 1.3 Biliary Tumor Market by Application
  8. 1.3.1 Global Biliary Tumor Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Biliary Tumor Market Dynamics
  1. 2.1 Biliary Tumor Industry Trends
  2. 2.2 Biliary Tumor Industry Drivers
  3. 2.3 Biliary Tumor Industry Opportunities and Challenges
  4. 2.4 Biliary Tumor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biliary Tumor Market Perspective (2021-2032)
  2. 3.2 Global Biliary Tumor Growth Trends by Region
  3. 3.2.1 Global Biliary Tumor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biliary Tumor Market Size by Region (2021-2026)
  5. 3.2.3 Global Biliary Tumor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biliary Tumor Revenue by Players
  2. 4.1.1 Global Biliary Tumor Revenue by Players (2021-2026)
  3. 4.1.2 Global Biliary Tumor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biliary Tumor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biliary Tumor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biliary Tumor Key Players Headquarters & Area Served
  7. 4.4 Global Biliary Tumor Players, Product Type & Application
  8. 4.5 Global Biliary Tumor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biliary Tumor Market CR5 and HHI
  11. 4.6.3 2025 Biliary Tumor Tier 1, Tier 2, and Tier 3
5 Biliary Tumor Market Size by Type
  1. 5.1 Global Biliary Tumor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biliary Tumor Revenue by Type (2021-2032)
  3. 5.3 Global Biliary Tumor Revenue Market Share by Type (2021-2032)
6 Biliary Tumor Market Size by Application
  1. 6.1 Global Biliary Tumor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biliary Tumor Revenue by Application (2021-2032)
  3. 6.3 Global Biliary Tumor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Biliary Tumor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Biliary Tumor Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 GlaxoSmithKline
  8. 7.2.1 GlaxoSmithKline Company Information
  9. 7.2.2 GlaxoSmithKline Business Overview
  10. 7.2.3 GlaxoSmithKline Biliary Tumor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Biliary Tumor Product Portfolio
  12. 7.2.5 GlaxoSmithKline Recent Developments
  13. 7.3 Southwest Oncology Group
  14. 7.3.1 Southwest Oncology Group Company Information
  15. 7.3.2 Southwest Oncology Group Business Overview
  16. 7.3.3 Southwest Oncology Group Biliary Tumor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Southwest Oncology Group Biliary Tumor Product Portfolio
  18. 7.3.5 Southwest Oncology Group Recent Developments
  19. 7.4 NuCana
  20. 7.4.1 NuCana Company Information
  21. 7.4.2 NuCana Business Overview
  22. 7.4.3 NuCana Biliary Tumor Revenue and Gross Margin (2021-2026)
  23. 7.4.4 NuCana Biliary Tumor Product Portfolio
  24. 7.4.5 NuCana Recent Developments
  25. 7.5 NeoGenomics
  26. 7.5.1 NeoGenomics Company Information
  27. 7.5.2 NeoGenomics Business Overview
  28. 7.5.3 NeoGenomics Biliary Tumor Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NeoGenomics Biliary Tumor Product Portfolio
  30. 7.5.5 NeoGenomics Recent Developments
8 North America
  1. 8.1 North America Biliary Tumor Revenue (2021-2032)
  2. 8.2 North America Biliary Tumor Revenue by Type (2021-2032)
  3. 8.2.1 North America Biliary Tumor Revenue by Type (2021-2026)
  4. 8.2.2 North America Biliary Tumor Revenue by Type (2027-2032)
  5. 8.3 North America Biliary Tumor Revenue Share by Type (2021-2032)
  6. 8.4 North America Biliary Tumor Revenue by Application (2021-2032)
  7. 8.4.1 North America Biliary Tumor Revenue by Application (2021-2026)
  8. 8.4.2 North America Biliary Tumor Revenue by Application (2027-2032)
  9. 8.5 North America Biliary Tumor Revenue Share by Application (2021-2032)
  10. 8.6 North America Biliary Tumor Revenue by Country
  11. 8.6.1 North America Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biliary Tumor Revenue by Country (2021-2026)
  13. 8.6.3 North America Biliary Tumor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biliary Tumor Revenue (2021-2032)
  2. 9.2 Europe Biliary Tumor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biliary Tumor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biliary Tumor Revenue by Type (2027-2032)
  5. 9.3 Europe Biliary Tumor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biliary Tumor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biliary Tumor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biliary Tumor Revenue by Application (2027-2032)
  9. 9.5 Europe Biliary Tumor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biliary Tumor Revenue by Country
  11. 9.6.1 Europe Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biliary Tumor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biliary Tumor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biliary Tumor Revenue (2021-2032)
  2. 10.2 China Biliary Tumor Revenue by Type (2021-2032)
  3. 10.2.1 China Biliary Tumor Revenue by Type (2021-2026)
  4. 10.2.2 China Biliary Tumor Revenue by Type (2027-2032)
  5. 10.3 China Biliary Tumor Revenue Share by Type (2021-2032)
  6. 10.4 China Biliary Tumor Revenue by Application (2021-2032)
  7. 10.4.1 China Biliary Tumor Revenue by Application (2021-2026)
  8. 10.4.2 China Biliary Tumor Revenue by Application (2027-2032)
  9. 10.5 China Biliary Tumor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biliary Tumor Revenue (2021-2032)
  2. 11.2 Asia Biliary Tumor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biliary Tumor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biliary Tumor Revenue by Type (2027-2032)
  5. 11.3 Asia Biliary Tumor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biliary Tumor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biliary Tumor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biliary Tumor Revenue by Application (2027-2032)
  9. 11.5 Asia Biliary Tumor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biliary Tumor Revenue by Country
  11. 11.6.1 Asia Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biliary Tumor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biliary Tumor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biliary Tumor Revenue (2021-2032)
  2. 12.2 SAMEA Biliary Tumor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biliary Tumor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biliary Tumor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biliary Tumor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biliary Tumor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biliary Tumor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biliary Tumor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biliary Tumor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biliary Tumor Revenue by Country
  11. 12.6.1 SAMEA Biliary Tumor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biliary Tumor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biliary Tumor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst